Mexiletine: Difference between revisions
m (Protected "Mexiletine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
Line 24: | Line 24: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 42: | Line 42: | ||
{{Antiarrhythmic agents}} | {{Antiarrhythmic agents}} | ||
[[Category:Antiarrhythmic agents]] | [[Category:Antiarrhythmic agents]] |
Revision as of 17:24, 9 August 2012
Clinical data | |
---|---|
Pregnancy category | |
Routes of administration | Oral, IV |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90% |
Protein binding | 50-60% |
Metabolism | Hepatic (CYP2D6 and 1A2- mediated) |
Elimination half-life | 10-12 hours |
Excretion | Renal (10%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C11H17NO |
Molar mass | 179.259 g/mol |
WikiDoc Resources for Mexiletine |
Articles |
---|
Most recent articles on Mexiletine |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mexiletine at Clinical Trials.gov Clinical Trials on Mexiletine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mexiletine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mexiletine Discussion groups on Mexiletine Patient Handouts on Mexiletine Directions to Hospitals Treating Mexiletine Risk calculators and risk factors for Mexiletine
|
Healthcare Provider Resources |
Causes & Risk Factors for Mexiletine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mexiletine (INN, sold under the trade name Mexitil®) belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat arrhythmias within the heart - or seriously irregular heartbeats. It slows nerve impulses in the heart and makes the heart tissue less sensitive. Dizziness, heartburn, nausea, nervousness, trembling, unsteadiness are common side effects. It is available in injection and capsule form.
Class IB antiarrhythmics decrease action potential duration by shortening the repolarization phase. This is achieved by blocking sodium channels[2].
Mexiletine may also be of use in patients experiencing refractory pain. (Sweetman, 2002) and is also effective for treating muscle stiffness resulting from myotonia congenita (Thomsen disease)
External links
References
- Peck T (2004). Pharmacology for Anaesthesia and Intensive Care (2nd ed. ed.). Cambridge University Press. ISBN 0-521-68794-2. Unknown parameter
|coauthors=
ignored (help) - Sweetman S (ed.) (2002). Martindale: The complete drug reference (33rd ed. ed.). London: Pharmaceutical Press. ISBN 0-85369-499-0.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Pages with citations using unsupported parameters
- CS1 maint: Extra text
- CS1 maint: Extra text: authors list
- Antiarrhythmic agents
- Drugs